Lung Cancer Europe

Startseite
Schweiz
Bern
Lung Cancer Europe

Kontaktinformationen, Karte und Wegbeschreibungen, Kontaktformulare, Öffnungszeiten, Dienstleistungen, Bewertungen, Fotos, Videos und Ankündigungen von Lung Cancer Europe, Nichtregierungsorganisation (NRO), Effingerstrasse 40, Bern.

Lung Cancer Europe brings together organisations across Europe to push for better lung cancer care, fairer access to testing and treatment, and stronger support for people affected by lung cancer.

07/06/2026

Lung cancer in women is a distinct disease. Different biology. Different risk factors. And still too often missed.

Yet the screening systems, clinical trials, and treatment guidelines were largely built without women in mind.

Last week at ASCO 2026, the data made that gap impossible to ignore. Incidence rising in younger women. Screening criteria that exclude those most at risk. A plenary trial where only 7% of participants were female.

Full blog post via link in bio.

06/06/2026

Europe loses €442 billion every year in productivity because of avoidable deaths from non-communicable diseases. Lung cancer is the leading cause of cancer death in Europe.

As EU leaders negotiate the next long-term budget, Lung Cancer Europe President Debra Montague has joined more than 490 healthcare experts, researchers, academics, and patient advocates in signing a joint letter calling for a dedicated, ring-fenced health budget in the next Multiannual Financial Framework (MFF) 2028-2034.

The European Parliament has already called for €10.05 billion to be allocated to health. The European Council meets on 18 and 19 June.

Read the full story via the link in bio.

05/06/2026

‼️ Landmark lung cancer research just published in Cell.

Scientists at the Francis Crick Institute and UCL, led by Professor Charles Swanton, have discovered a 14-protein blood signature that predicts lung cancer more than 5 years before diagnosis and it works in never-smokers too.

Think of it like a smoke alarm for your lungs. It detects dangerous inflammation years before a tumour develops. And it could identify who would benefit from a drug to damp that inflammation down - cutting lung cancer risk nearly in half.

This could finally give us something lung cancer has never had: a way to prevent it in the people most at risk.

🔗 https://www.lungcancereuropenews.eu/news/blood-test-predicts-lung-cancer-five-years-early

📷 © Michael Schwimmer and Jeroen Claus (Phospho Biomedical Animation) / ERC

04/06/2026

A drug that stops lung cancer hiding from the immune system has shown encouraging results in an early clinical trial, according to new research presented at ASCO 2026 and widely covered this week in the media.

Immunotherapy can work well for some people with lung cancer, but not for everyone, and sometimes it stops working. This is often because cancer cells find ways to hide from the immune system’s T-cells.

GRWD5769 works by blocking the mechanism that allows cancer cells to hide. In the EMITT-1 trial, more than half of the lung cancer participants whose immunotherapy had already stopped working saw their disease stabilise for at least six months.

It is early stage research, but the results across six hard-to-treat cancer types are encouraging.

03/06/2026

ASCO is the American Society of Clinical Oncology. Its annual meeting brings together more than 50,000 oncology professionals from over 150 countries. This year it was in Chicago, and for the first time, Lung Cancer Europe was there.

Lung cancer is the world’s leading cause of cancer death. The research presented at ASCO feeds into the clinical guidelines and treatment decisions that affect people with lung cancer across Europe. That is why we came.

One of the most powerful things about a meeting like this is that cancer research is translational. Discoveries in a lab, data presented in a conference hall, conversations between advocates and researchers, all of it can eventually reach the people who need it most.

Lung cancer is a global problem. But so is the effort to solve it.

02/06/2026

Fantastic news! The European Commission has approved tarlatamab (IMDYLLTRA) for adults with relapsed extensive-stage small cell lung cancer after platinum-based chemotherapy.

Small cell lung cancer is one of the most aggressive forms of the disease. Most people respond well to first-line treatment, but relapse is common, and options after that have historically been limited.

Tarlatamab works by bringing the immune system’s T-cells into direct contact with cancer cells, helping them find and destroy the tumour.

The approval is based on phase 3 data showing a 40% reduction in risk of death compared to chemotherapy. New data presented at ASCO 2026 this week also showed a 49% reduction in risk of death in people with brain metastases.

As Lung Cancer Europe President Debra Montague said: “This represents meaningful progress and underscores the urgent need for innovation in lung cancer care.”

02/06/2026

Our June newsletter is out today, and this one’s coming to you from Chicago 🇺🇸

Find out why Lung Cancer Europe is at ASCO for the first time and what it means for lung cancer in Europe.

We’ll also be heading to Korea later this year and we have big news about why.

There’s plenty happening in Brussels too, plus find out how you can get involved in our 2026 Get Checked! awareness campaign.

It’s all in this month’s update. 🔗 in bio and in comments.

31/05/2026

Today is World No To***co Day.

24% of adults in the European Region use to***co - the highest rate in the world. And it is falling too slowly.

To***co is the single largest preventable cause of lung cancer. But lung cancer can affect anyone, including people who have never smoked. No one deserves to get cancer, and no one should face stigma alongside a diagnosis.

To***co dependence is a medical condition. Most people who use to***co want to stop, but quitting is hard and people deserve real support to do it not judgement.

At the same time, a new generation is being actively recruited into ni****ne addiction. The to***co industry has been targeting young people for decades - through flavours, social media, influencers and products designed to be hidden from parents and teachers. The products have changed. The strategy has not.

The EU is consulting on strengthening its to***co laws right now, with a deadline of 15 June 2026. We support that call and have shared our thoughts on what stronger regulation should look like.

Read more - click the link in our bio.

***coDay ***coControl

30/05/2026

Lung Cancer Europe is at ASCO 2026 in Chicago for the first time.

We’re not here because it’s a huge, well known, prestigious international oncology event, although it’s all those things. We’re here because lung cancer is moving quickly, and the discussions at meetings like this influence the future of care.

Studies presented at ASCO feed into global clinical guidelines, regulatory decisions, treatment pathways and policy. Over time, they affect what people with lung cancer in Europe may be able to access. That’s why this meeting matters to a European lung cancer advocacy organisation.

The theme of this year’s meeting is “The Science and Practice of Translation: Improving Cancer Outcomes Worldwide.” That aligns exactly with what we are here to do.

ASCO brings together researchers, clinicians, advocates, professional societies, regulators and industry from across the world. Lung cancer is the world’s leading cause of cancer death. A global issue needs a global community.

Our President Debra Montague and Vice President Angeliki Souri are here alongside our Head of Operations Melanie De Coster, meeting with partners and supporters and following the lung cancer programme closely.

29/05/2026

Lung cancer care is changing faster than many people realise.

Targeted therapies, biomarker testing, immunotherapy and new treatment approaches are changing what may be possible for people affected by lung cancer.

But progress in science does not automatically mean progress for everyone.

Across Europe, people can still face late diagnosis, delays in biomarker testing, limited access to clinical trials, and differences in whether newer treatments are available where they live.

A new policy paper, Europe at a Crossroads: Securing Lasting Leadership in Cancer Care and Innovation, looks at what Europe needs to do next as Europe’s Beating Cancer Plan moves towards its conclusion in 2027.

Europe must keep setting the pace in cancer care, with innovation reaching people faster and more fairly.

Read more through the link in our bio.

Adresse

Effingerstrasse 40
Bern
3008

Webseite

https://linktr.ee/lungcancereur

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Lung Cancer Europe erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.